Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies
Our exceptional responders with high-grade gliomas suggest that biomarker-matched targeted therapy can benefit select patients with high-grade glioma and warrants prospective clinical trials.
Authors
- M. Ahluwalia
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Umut Dişel (ORCID: https://orcid.org/0000-0003-0028-5176)
- Aditya Varnam Shreenivas (ORCID: https://orcid.org/0000-0002-8523-1523)
- Shumei Kato (ORCID: https://orcid.org/0000-0003-1193-1815)
- Ayca Ersen Danyeli
Institutions
- Baptist Hospital of Miami (US)
- Froedtert Hospital (US)
- Acıbadem University (TR)
- Baptist Health South Florida (US)
- City of Hope (US)
- Acıbadem Adana Hospital (TR)
- Moores Cancer Center
Publication Details
- Journal
- Journal of Immunotherapy and Precision Oncology
- Published
- 2026-03-16
- DOI
- https://doi.org/10.36401/jipo-25-34
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00